Kenvue Inc. (KVUE)
| Market Cap | 27.85B |
| Revenue (ttm) | 15.14B |
| Net Income (ttm) | 1.42B |
| Shares Out | 1.92B |
| EPS (ttm) | 0.74 |
| PE Ratio | 19.61 |
| Forward PE | 13.67 |
| Dividend | $0.83 (5.72%) |
| Ex-Dividend Date | Aug 13, 2025 |
| Volume | 29,927,296 |
| Open | 14.90 |
| Previous Close | 15.08 |
| Day's Range | 14.43 - 14.93 |
| 52-Week Range | 14.05 - 25.17 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | 21.08 (+45.28%) |
| Earnings Date | Nov 6, 2025 |
About KVUE
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other... [Read more]
Financial Performance
In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price target is $21.08, which is an increase of 45.28% from the latest price.
News
Embattled Tylenol Maker Kenvue Hires New Marketing Chief
The company plans to name snack food executive Jon Halvorson as it faces a crisis over concerns of links between Tylenol and autism.
Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks
The makers of Tylenol, Johnson & Johnson and Kenvue , were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug's links to autism and attention deficit h...
Texas sued Tylenol maker Kenvue, alleging it deceived pregnant women about risks associated with autism
The suit alleges that the Tylenol maker engaged in deceptive marketing by advertising the product as safe to use while pregnant.
49 October Hi-Yield S&P Aristocrats: 5 To Buy
“Hi-Yield S&P Aristocrats... in the S&PComposite1500Index… combine two key-traits: (1) a long track-record of consistently-raising-dividends (typically at-least 20–25 consecutive-years, but not-always...
Time To Buy The Dip In Kenvue Stock?
Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its stock price in recent months. The shares are currently priced around $15, whic...
Kenvue to Announce Third Quarter 2025 Results on November 6, 2025
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025. The company will host a conference call and ...
US IPO Weekly Recap: 5 Small IPOs Debut, As Government Shutdown Drags On
Five small IPOs debuted and four SPACs listed this week as the government shutdown continues to complicate listings. Two sizable IPOs are scheduled for the week ahead, both of which launched after the...
Starboard Value CEO: We're thrilled to own Kenvue at this valuation
Starboard Value CEO Jeff Smith joins CNBC's David Faber from 13D Monitor's Active-Passive Investor Summit.
Kenvue Urges FDA to Reject Request for Autism Warning on Tylenol
Kenvue urged the Food and Drug Administration to deny a proposal to add further warnings to acetaminophen products after the Trump Administration linked Tylenol use during pregnancy to autism.
Kenvue urges US FDA to deny request for Tylenol's autism warning
Kenvue has urged U.S. regulators to reject a request for a warning of autism on its popular over-the-counter pain medication Tylenol for use during pregnancy, according to a petition.
September Readers ID'd 17 Ideal 'Safer' Dividends In 39 Dogs
This article highlights top ReFa/Ro dividend stocks for September 2025, focusing on high yield and analyst-projected returns through September 2026. MFA Financial, Hafnia, and Energy Transfer lead the...
Top Stock Movers Now: Oracle, Newmont, Kenvue, American Express, and More
Major U.S. equities indexes climbed at midday Friday as regional bank stocks rebounded from yesterday's losses after a flurry of corporate earnings reports. The Dow, S&P 500, and Nasdaq were all highe...
Kenvue: A Rock Solid 5% Yield
Kenvue offers stable financials, a robust 5% dividend yield, and the stock trades at a significant discount to peers and historical averages. KVUE's recent decline, driven by Tylenol-related headlines...
Albert Invent Partners with Kenvue to Build the Future of Consumer Health Products With the Help of AI
SUMMIT, N.J. & OAKLAND, Calif.--(BUSINESS WIRE)--Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Zyrtec®...
Trump's Tylenol claims limit M&A options for parent company Kenvue
Tylenol maker Kenvue was already having a painful year before U.S. President Donald Trump and his health secretary got involved.
Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs
Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deli...
Buy 2 Ideal Dividend Kings Of 25 'Safer' In October's 56
This October's Dividend Kings list features 56 stocks, with Kenvue and United Bankshares meeting the ideal "fair price" yield criteria. Analysts project the top-ten Dividend Kings could deliver 19.2% ...
US Republicans and Democrats split on party lines on Trump's Tylenol-autism claim, KFF poll finds
Republicans and Democrats are divided along party lines as to whether they believe the U.S. government's claim that women who take Tylenol during pregnancy are raising the risk of autism in their unbo...
Does Tylenol cause autism? Researchers can use ‘natural experiments' to study the link, write Drs.
In the absence of randomized trials on the effects of acetaminophen, researchers need to use ‘natural experiments' to develop better guidance for patients.
Kenvue: Trump-Era Volatility Presents A More Attractive Opportunity, But Headwinds Remain
Kenvue faces near-term headwinds from Tylenol-autism allegations, macro uncertainty, and segment underperformance, but offers long-term income potential. Recent leadership changes and a focus on core ...
The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.
The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.
Trump repeats Tylenol and vaccine claims, defying medical community outcry
U.S. President Donald Trump on Friday repeated his call for pregnant women and young children to stop using popular pain medication Tylenol, defying widespread criticism from medical groups, and offer...
51 September S&P Hi-Yield Aristocrats: 5 To Buy
The article highlights the top ten S&P Hi-Yield Aristocrats for September, with nine stocks offering attractive yields and fair pricing for dividend investors. Analyst forecasts project potential net ...
RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?
Tylenol may be only the beginning.
Attorneys urge court overseeing Tylenol autism lawsuits to consider Trump administration's stance
Families appealing the dismissal of their lawsuits alleging that Kenvue's Tylenol or generic versions of the pain-relief medication caused their children's autism are asking an appeals court to consid...